Spyre Therapeutics (SYRE) earnings
Spyre Therapeutics (SYRE) reported net income of -$155.20M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$208.02M. Figures as of 18 Nov 2026, 04:58 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- -$155.20M
- Highest on record
- -$10.35Mfiscal 2014
- Lowest on record
- -$338.79Mfiscal 2023
- Fiscal years on record
- 122014–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Spyre Therapeutics earnings, in more detail
Across the 12 fiscal years on record (2014–2025), the highest was -$10.35M in fiscal 2014 and the lowest -$338.79M in fiscal 2023.
Earnings (net income) by fiscal year
Spyre Therapeutics earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | -$155.20M | — | |
| 2024 | -$208.02M | — | |
| 2023 | -$338.79M | — | |
| 2022 | -$83.82M | — | |
| 2021 | -$65.80M | — | |
| 2020 | -$80.89M | — | |
| 2019 | -$78.25M | — | |
| 2018 | -$44.35M | — | |
| 2017 | -$27.24M | — | |
| 2016 | -$21.70M | — | |
| 2015 | -$11.30M | — | |
| 2014 | -$10.35M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Earnings (net income) at health care companies of similar size
| Company | Earnings (net income) | Fiscal year |
|---|---|---|
| Vaxcyte PCVX | -$766.63M | 2025 |
| Bio-Rad Laboratories BIO | $759.90M | 2025 |
| Molina Healthcare MOH | $472.00M | 2025 |
| Spyre Therapeutics SYRE | -$155.20M | 2025 |
| Qiagen QGEN | $424.88M | 2025 |
| Insulet PODD | $247.10M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Spyre Therapeutics, figure by figure
- Spyre Therapeutics market cap
- Spyre Therapeutics revenue
- Spyre Therapeutics earnings per share (EPS)
- Spyre Therapeutics P/E ratio
- Spyre Therapeutics P/S ratio
- Spyre Therapeutics P/B ratio
- Spyre Therapeutics free cash flow
- Spyre Therapeutics operating margin
- Spyre Therapeutics dividend
- Spyre Therapeutics shares outstanding
- Spyre Therapeutics total debt
- Spyre Therapeutics cash on hand
- Spyre Therapeutics total assets
- Spyre Therapeutics return on equity (ROE)
- Spyre Therapeutics return on invested capital (ROIC)
Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value
Spyre Therapeutics earnings: questions and answers
What is Spyre Therapeutics's net income?
Spyre Therapeutics (SYRE) reported net income of -$155.20M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$208.02M.
What are the highest and lowest net income figures on record for Spyre Therapeutics?
Across the 12 fiscal years on record (2014–2025), the highest was -$10.35M in fiscal 2014 and the lowest -$338.79M in fiscal 2023.
How is Spyre Therapeutics's net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Spyre Therapeutics (SYRE) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/earnings
Underlying data: the company's filings with the SEC and Yahoo Finance.